ClinicalTrials.gg
CompletedNCT03268954PANTHERUpdated Oct 29, 2025Results posted

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

A Phase 3 interventional study of Azacitidine and Pevonedistat in Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic and Leukemia, Myeloid, Acute, sponsored by Takeda. Completed at 242 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
454
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
2nd of 126
454 · median 38
Started
2017
with 6 others
Phase 3
9 of 130
1 open now
Registered
94th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 2nd largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2017, is one of 9 in phase 3, and was the 94th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).

Read the detailed description

The drug being tested in this study is called pevonedistat. Pevonedistat is being tested to treat people with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (AML) as a combination treatment with azacitidine. This study will look at the overall survival, event-free survival and response to treatment in people who take pevonedistat and azacitidine when compared to people who take single-agent azacitidine.

The study will enroll approximately 450 participants. Once enrolled, participants will be randomly assigned in 1:1 ratio (by chance, like flipping a coin) to one of the two treatment groups in 28-day treatment cycles:

  • Pevonedistat 20 mg/m\^2 and azacitidine 75 mg/m\^2 combination
  • Single-agent azacitidine 75 mg/m\^2

All participants will receive azacitidine via intravenous or subcutaneous route. Participants randomized to the combination arm will also receive pevonedistat intravenous infusion.

This multi-center trial will be conducted Spain, Belgium, Brazil, Canada, Czech Republic, France, Germany, Israel, Italy, the United States, Australia, Greece, Japan, Mexico, Poland, Russia, Korea, Turkey, China and United Kingdom. The overall time to participate in this study is approximately 63 months. Participants will attend the end-of-treatment visit 30 days after the last dose of study drug or before the start of subsequent anti-neoplastic therapy if that occurs sooner.

Participants with HR MDS or CMML will have EFS follow-up study visits every month if their disease has not transformed to AML and they have not started subsequent therapy. Participants with low-blast AML will have response follow-up study visits every month until they relapse from CR or meet the criteria for PD. All participants will enter OS follow-up (contacted every 3 months) when they have confirmed transformation to AML (for participants with HR MDS or CMML at enrollment) or experienced PD (for participants with low-blast AML at study enrollment).

03

Conditions studied

  • Myelodysplastic Syndrome
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myeloid, Acute

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or CMML (i.e., with white blood cell [WBC] \<13,000/microliter [mcL]) or low-blast acute myelogenous leukemia (AML).
  2. Has MDS or CMML and must also have one of the following Prognostic Risk Categories, based on the Revised International Prognostic Scoring System (IPSS-R):

    • Very high (>6 points).
    • High (>4.5-6 points).
    • Intermediate (>3-4.5 points): a participant determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of >=5% bone marrow myeloblasts.
  3. (ECOG) status of 0, 1, or 2.
  4. Participants with AML (20%-30% blasts) must have a treatment-related mortality (TRM) score >=4 for intensive, induction chemotherapy as calculated using the simplified model described by Walter and coworkers.

Calculation of TRM score:

  • 0 for (age \<61 years), +2 for (age 61-70 years), +4 for (age >=71 years).
  • + 0 for (PS=0), +2 for (PS=1), +4 for (PS >1).
  • + 0 for ( \<50), +1 for (platelets >=50).

Exclusion criteria

Exclusion Criteria:

  1. Has previous treatment for HR MDS or CMML or low-blast AML with chemotherapy or other antineoplastic agents including hypomethylating agent (HMAs) such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug.
  2. Has acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
  3. Participants with AML with a WBC count >50,000/mcL. Participants who are cytoreduced with leukapheresis or with hydroxyurea may be enrolled if they meet the eligibility criteria.
  4. Is eligible for intensive chemotherapy and/or stem cell transplantation. The reason a participant is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation may consist of one or more of the following factors:

    • Age >75.
    • Comorbidities.
    • Inability to tolerate intensive chemotherapy (e.g., participants with AML with 20%-30% blasts and TRM >=4).
    • Physician decision (e.g., lack of available stem cell donor).
    • The reason a participant is not eligible should be documented in the electronic case report form (eCRF).
  5. Has either clinical evidence of or history of central nervous system involvement by AML.
  6. Has active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
  7. Is diagnosed or treated for another within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease.
  8. Has nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
  9. Has (PT) or aPTT >1.5× (ULN) or active uncontrolled coagulopathy or bleeding disorder. Participants therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded from enrollment.
  10. Has known (HIV) seropositive.
  11. Has known surface antigen seropositive, or known or suspected active infection. Note: Participants who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load.
  12. Has known hepatic cirrhosis or severe preexisting hepatic impairment.
  13. Has known cardiopulmonary disease defined as unstable angina, arrhythmia, congestive heart failure ( Class III or IV), and/or myocardial infarction within 6 months before first dose, or severe pulmonary hypertension.
  14. Has treatment with strong cytochrome P 3A () inducers within 14 days before the first dose of pevonedistat.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
454 participants (actual)

Study arms

  • Experimental
    Azacitidine 75 mg/m^2

    Participants were administered azacitidine 75 milligram per square meter (mg/m\^2) intravenous (IV) or subcutaneous (SC) injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.

    Drug: Azacitidine

  • Experimental
    Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2

    Participants were administered azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.

    Drug: Azacitidine · Drug: Pevonedistat

Interventions

  • Azacitidine intravenous or subcutaneous formulation.

  • Pevonedistat intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS)

    EFS was defined as the time from randomization to the date of an EFS event. An EFS event was defined as death or transformation to acute myelogenous leukemia (AML) (World Health Organization \[WHO\] classification as a participant having greater than 20 % blasts in the blood or marrow and an increase of blast count by 50%), whichever event occurred first, in participants with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemias (CMML). An EFS event was defined as death in participants with low-blast AML.

    Time frame: From randomization until transformation to acute myeloid leukemia, or death due to any cause: up to approximately 42 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time from randomization to death from any cause.

    Time frame: Up to approximately 6.9 years

  2. Kaplan-Meier Estimates of Six-Month Survival Rate

    Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of Month 6 from randomization are presented.

    Time frame: Month 6

  3. Kaplan-Meier Estimates of One-Year Survival Rate

    Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of the first year from randomization are presented.

    Time frame: Year 1

  4. Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30

    30-day mortality was defined as number of participants who died within 30 days from the first dose of study drug.

    Time frame: Up to Day 30

  5. Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60

    60-day mortality was defined as number of participants who died within 60 days from the first dose of study drug.

    Time frame: Up to Day 60

  6. Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants

    Time to AML transformation in HR MDS and CMML participants was defined as time from randomization to documented AML transformation as determined by the independent review committee (IRC) assessment. Participants who died before progression to AML were censored. Transformation to AML was defined, according to WHO classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.

    Time frame: From randomization until transformation to AML (up to approximately 42 months)

  7. Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi)

    CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 gram per deciliter (g/dL) hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).

    Time frame: From randomization until CR (up to approximately 42 months)

  8. Number of Participants With CR and Marrow CR

    Disease responses for HR MDS or CMML are based on the International Working Group (IWG) Response Criteria for MDS. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and \>=11 g/dL Hgb, \>=100\*10\^9/L platelets (pl), \>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment.

    Time frame: From randomization until CR or marrow CR (up to approximately 42 months)

  9. Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI)

    Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. HI: Hgb increase \>=1.5 g/dL if \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.

    Time frame: From randomization until, CR, PR or HI (up to approximately 42 months)

  10. Number of Participants With CR and Marrow CR and PR

    Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%.

    Time frame: From randomization until CR or Marrow CR and PR (up to approximately 42 months)

  11. Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI)

    Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increases from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increases by 100% and absolute increases of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.

    Time frame: From randomization until CR, marrow CR, PR or HI (up to approximately 42 months)

  12. Number of Participants With Overall Response (OR)

    Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR or PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR:morphologic leukemia-free state\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in bone marrow aspirate.

    Time frame: From randomization until CR and PR or CR, CRi and PR (up to approximately 42 months)

  13. Number of Participants With Overall Response 2 (OR2)

    OR2=participant with best overall response of CR+PR+HI in HR MDS/CMML participants,or of CR+CRi+PR in low-blast AML participants.CR:≤5% myeloblasts with normal maturation of all bone marrow(BM)cell lines,≥11g/dL Hgb,≥100\*10\^9/L pl,≥1.0\*10\^9/L neutrophils,0% blasts in peripheral blood;PR:all CR criteria met except BM blasts ≥50% decrease over pretreatment but still \>5%;HI:Hgb increase(inc) ≥1.5g/dL if baseline(BL)\<11 g/dL;pl inc≥30\*10\^9/L if BL\>20\*10\^9/L or inc from \<20\*10\^9/L to \>20\*10\^9/L and by 100%;neutrophil inc by 100%;absolute inc of \>0.5\*10\^9/L if BL\<100\*10\^9/L.For low-blast AML-CR:morphologic leukemia-free state \>1.0\*10\^9 neutrophils,≥100\*10\^9/L pl,transfusion independence,no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl\<100\*10\^9/L;PR:all CR hematological values but ≥50% decrease in BM aspirate.Number of responders determined by independent review committee(IRC) assessment.

    Time frame: From randomization until, CR, PR or HI or CR, CRi or PR (up to approximately 42 months)

  14. Duration of Complete Remission (CR)

    Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML) or relapse after CR or PR (participants with HR MDS/CMML). Disease responses for HR MDS or CMML are based on the Modified IWG Response Criteria for MDS and for low-blast AML on the Revised IWG Response Criteria for AML. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).

    Time frame: From CR until first documentation of PD or relapse from CR or relapse after CR or PR (up to approximately 42 months)

  15. Duration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi)

    Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML). Disease responses for low-blast AML were based on the Revised IWG Response Criteria for AML. CR is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).

    Time frame: From CR until first documentation of PD or relapse from CR or relapse after CR or PR (up to approximately 42 months)

  16. Duration of Overall Response (OR)

    Duration of OR: response to first documentation of PD or relapse from CR for low-blast AML or relapse after CR or PR for HR MDS/CMML. Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR+PR for HR MDS/CMML and CR+Cri+ PR for low-blast AML.CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR:all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR: morphologic leukemia-free state \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with CRi: fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in % of blasts in bone marrow aspirate.

    Time frame: Up to approximately 42 months

  17. Duration of Overall Response 2 (OR2)

    Duration of OR2: from date of first documentation of CR+PR+HI to first documentation of PD/relapse after CR/PR for responders of CR+PR+HI for HR MDS/CMML and CR,CRi,PR for low-blast AML. For HR MDS/CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb, \>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment, still \>5%; HI:Hgb inc \>=1.5 g/dL if baseline \<11 g/dL; pl inc\>=30\*10\^9/L if baseline\>20\*10\^9/L or inc from\<20\*10\^9/L to\>20\*10\^9/L by at least 100%; neutrophil inc by 100% and absolute inc of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L;PR:all CR hematological values but\>=50% decrease in bone marrow aspirate.

    Time frame: Up to approximately 42 months

  18. Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence

    A participant was defined as RBC or platelet-transfusion independent if he/she received no RBC or platelet transfusions for a period of at least 8 weeks before the first dose of study drug through 30 days after the last dose of any study drug. Rate of transfusion independence was defined as number of participants who became transfusion independent divided by the number of participants who were transfusion dependent at Baseline.

    Time frame: Up to approximately 42 months

  19. Duration of Red Blood Cells (RBCs) and Duration of Platelet-transfusion Independence and Duration of Red Blood Cells (RBCs) and Platelet-transfusion Independence

    Duration of RBC and platelet transfusion independence was defined as the longest time between the last RBC and/or platelet transfusion before the start of the RBC and/or platelet transfusion-independent period and the first RBC and/or platelet transfusion after the start of the transfusion-independent period, which occurs \>= 8 weeks later.

    Time frame: Up to approximately 42 months

  20. Time to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi)

    Time to first CR or PR is defined as the time from randomization to first documented CR or PR, whichever occurs first. Disease responses for HR MDS or CMML or low-blast AML cycle 6 are based on Modified IWG Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. For HR MDS or CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%; For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9/L neutrophils, pl\>=100\*10\^9/L, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.

    Time frame: From randomization until CR or PR (up to approximately 42 months)

  21. Number of Participants With Hematologic Improvement (HI)

    Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline \>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.

    Time frame: From randomization until HI (up to approximately 42 months)

  22. Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML

    Inpatient hospital admission data was collected through transformation to AML (HR MDS/CMML participants) or disease progression (low-blast AML participants) or until initiation of subsequent therapy (all participants), whichever occurred first. Transformation to AML is defined, according to WHO Classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.

    Time frame: From randomization until transformation to AML or until initiation of subsequent therapy (up to approximately 42 months)

  23. Time to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death

    Time to PD, relapse after CR(low-blast AML), relapse after CR or PR(HR MDS/CMML), or death,defined as time from date of randomization until date of first documentation of PD,relapse after CR(low-blast AML),relapse after CR or PR(HR MDS/CMML),or death due to any cause, whichever occurs first. In HR MDS/CMML,PD: Participants with\<5% blasts:\>=50% inc \>5% blasts, with 5%-9% blasts:\>=50% inc\>10% blasts, with 10%-19% blasts:\>=50% inc \>20% blasts,with 20%-30% blasts, at least 50% decrement from maximum remission/response in granulocytes or pl or reduction in Hgb by\>=2 g/dL/new transfusion dependence.Relapse after CR or PR: return to pretreatment bone marrow blast %/Decrement of \>=50% from maximum remission/response levels in granulocytes/pl/reduction in Hgb conc.\>=1.5 g/dL/transfusion dependence. In AML,PD:\>50% inc in bone marrow blasts to \>30% blasts,\>50% inc in circulating blasts to\>30% blasts in peripheral blood, Development of extramedullary disease/new sites of extramedullary leukemia.

    Time frame: From randomization until PD, relapse after CR, or relapse after CR or PR, or death due to any cause, whichever occurs first (up to approximately 42 months)

  24. Change From Baseline in Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30

    The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The change from baseline at end of treatment is reported.

    Time frame: Baseline, at approximately 58 months

  25. Number of Participants With Overall Response in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group

    Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR + PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR: morphologic leukemia-free state, \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl\<100\*10\^9/L; PR: all CR hematological values but\>=50% decrease in the percentage of blasts to 5% to 25% in bone marrow aspirate.

    Time frame: From randomization until CR, CRi and PR (up to approximately 42 months)

  26. Event-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group

    Event was defined as death or transformation to AML in participants with MDS or CMML, whichever occurred first. Transformation to AML was defined, according to World Health Organization (WHO) Classification as a participant having \>20% blasts in the blood or marrow and increase of blast count by 50%. Event was defined as death in participants with low-blast AML.

    Time frame: From randomization until transformation to AML if eligible or death (up to approximately 42 months)

  27. Overall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group

    OS was calculated from date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored as of the date the participant was last known to be alive.

    Time frame: From randomization until death (up to approximately 42 months)

  28. Number of Participants With Overall Response by Cycle 6

    Responses for HR MDS/CMML are based on Modified International Working Group (IWG) Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR and PR for HR MDS/CMML and CR+CR with incomplete blood count recovery(CRi)+PR for low-blast AML. CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11g/dL hemoglobin (Hgb),\>=100\*10\^9/L platelet (pl),\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood, and PR:all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR:morphologic leukemia-free state,\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L/thrombocytopenia (pl\<100\*10\^9/L); PR:all CR hematological values but\>=50% decrease in percentage of blasts to 5%-25% in bone marrow aspirate.

    Time frame: Up to Cycle 6 (up to approximately Day 168)

07

Results

Posted Sep 22, 2022

Participant flow

Participants took part in the study at 130 investigative sites globally from 28 November 2017 to 14 October 2024.

Participant flow — Overall Study
MilestoneAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Started227227
Safety population220223
Completed195199
Not completed3228
Withdrew: Withdrawal by subject2717
Withdrew: Lost to follow-up23
Withdrew: Reason not specified38

Outcome measures

PrimaryEvent-Free Survival (EFS)

EFS was defined as the time from randomization to the date of an EFS event. An EFS event was defined as death or transformation to acute myelogenous leukemia (AML) (World Health Organization \[WHO\] classification as a participant having greater than 20 % blasts in the blood or marrow and an increase of blast count by 50%), whichever event occurred first, in participants with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemias (CMML). An EFS event was defined as death in participants with low-blast AML.

Time frame:
From randomization until transformation to acute myeloid leukemia, or death due to any cause: up to approximately 42 months
Reported as:
Median · months
Event-Free Survival (EFS)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Event-Free Survival (EFS)15.7 (14.42 to 19.68)17.7 (13.63 to 20.24)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.557 · Hazard ratio (hr): 0.968 · 95% CI 0.757 to 1.238HR:unadjusted stratified Cox proportional hazard regression with stratification(low-blast AML,IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\<1:better prevention of EFS in combination arm than azacitidine arm.
SecondaryOverall Survival (OS)

Overall survival was defined as the time from randomization to death from any cause.

Time frame:
Up to approximately 6.9 years
Reported as:
Median · months
Overall Survival (OS)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Overall Survival (OS)16.8 (14.92 to 20.11)20.3 (17.97 to 22.60)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.152 (P-value comparing OS between treatment groups was based on the 1-sided Cui-Hung-Wang weighted unstratified log-rank test.) · Hazard ratio (hr): 0.888 · 95% CI 0.709 to 1.113HR:unadjusted stratified Cox proportional hazard regression with stratification(low-blast AML,IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\<1: longer survival time in combination arm than azacitidine arm.
SecondaryKaplan-Meier Estimates of Six-Month Survival Rate

Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of Month 6 from randomization are presented.

Time frame:
Month 6
Reported as:
Number · percentage probability
Kaplan-Meier Estimates of Six-Month Survival Rate
percentage probabilityAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Kaplan-Meier Estimates of Six-Month Survival Rate0.825 (0.767 to 0.869)0.810 (0.752 to 0.856)
SecondaryKaplan-Meier Estimates of One-Year Survival Rate

Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of the first year from randomization are presented.

Time frame:
Year 1
Reported as:
Number · percentage probability
Kaplan-Meier Estimates of One-Year Survival Rate
percentage probabilityAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Kaplan-Meier Estimates of One-Year Survival Rate0.693 (0.626 to 0.751)0.646 (0.578 to 0.706)
SecondaryThirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30

30-day mortality was defined as number of participants who died within 30 days from the first dose of study drug.

Time frame:
Up to Day 30
Reported as:
Count of participants · Participants
Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 3065
SecondarySixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60

60-day mortality was defined as number of participants who died within 60 days from the first dose of study drug.

Time frame:
Up to Day 60
Reported as:
Count of participants · Participants
Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 601514
SecondaryTime to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants

Time to AML transformation in HR MDS and CMML participants was defined as time from randomization to documented AML transformation as determined by the independent review committee (IRC) assessment. Participants who died before progression to AML were censored. Transformation to AML was defined, according to WHO classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.

Time frame:
From randomization until transformation to AML (up to approximately 42 months)
Reported as:
Median · months
Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
HR MDS Participants35.6 (26.51 to NA)NA (23.29 to NA)
HR CMML ParticipantsNA (NA to NA)NA (NA to NA)
HR MDS/CMML Participants35.6 (29.04 to NA)NA (24.28 to NA)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.562 (P-value comparing time to AML Transformation between treatment groups was based on 1-sided stratified log-rank test stratified by IPSS-R risk groups of very high, high, or intermediate for HR MDS.) · Hazard ratio (hr): 1.037 · 95% CI 0.660 to 1.630HR:unadjusted stratified Cox proportional HazardRegression with stratification(IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\<1:better prevention of AML transformation in combination arm than azacitidine arm.
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.603 (P-value comparing time to AML Transformation between treatment groups was based on 1-sided stratified log-rank test stratified by IPSS-R risk groups of very high, high, or intermediate for HR CMML.) · Hazard ratio (hr): 1.512 · 95% CI 0.068 to 33.773HR:unadjusted stratified Cox proportional HazardRegression with stratification(IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\<1:better prevention of AML transformation in combination arm than azacitidine arm.
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.558 (P-value comparing time to AML Transformation between treatment groups was based on 1-sided stratified log-rank test stratified by IPSS-R risk groups of very high, high, or intermediate for HR CMML/MDS.) · Hazard ratio (hr): 1.034 · 95% CI 0.663 to 1.610HR:unadjusted stratified Cox proportional HazardRegression with stratification(IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\<1:better prevention of AML transformation in combination arm than azacitidine arm.
SecondaryNumber of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi)

CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 gram per deciliter (g/dL) hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).

Time frame:
From randomization until CR (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi)
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi)7163
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.374 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Absolute rate difference: -4.18 · 95% CI -13.18 to 4.83
SecondaryNumber of Participants With CR and Marrow CR

Disease responses for HR MDS or CMML are based on the International Working Group (IWG) Response Criteria for MDS. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and \>=11 g/dL Hgb, \>=100\*10\^9/L platelets (pl), \>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment.

Time frame:
From randomization until CR or marrow CR (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With CR and Marrow CR
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With CR and Marrow CR9187
SecondaryNumber of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI)

Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. HI: Hgb increase \>=1.5 g/dL if \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.

Time frame:
From randomization until, CR, PR or HI (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI)
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI)7776
SecondaryNumber of Participants With CR and Marrow CR and PR

Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%.

Time frame:
From randomization until CR or Marrow CR and PR (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With CR and Marrow CR and PR
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With CR and Marrow CR and PR9187
SecondaryNumber of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI)

Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increases from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increases by 100% and absolute increases of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.

Time frame:
From randomization until CR, marrow CR, PR or HI (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI)
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI)112117
SecondaryNumber of Participants With Overall Response (OR)

Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR or PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR:morphologic leukemia-free state\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in bone marrow aspirate.

Time frame:
From randomization until CR and PR or CR, CRi and PR (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Overall Response (OR)
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With Overall Response (OR)7364
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.329 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test stratified by low-blast AML, Revised International Prognostic Scoring System (IPSS-R) risk groups of very high, high, or intermediate for HR MDS/CMML.) · Absolute rate difference: -4.67 · 95% CI -13.72 to 4.39
SecondaryNumber of Participants With Overall Response 2 (OR2)

OR2=participant with best overall response of CR+PR+HI in HR MDS/CMML participants,or of CR+CRi+PR in low-blast AML participants.CR:≤5% myeloblasts with normal maturation of all bone marrow(BM)cell lines,≥11g/dL Hgb,≥100\*10\^9/L pl,≥1.0\*10\^9/L neutrophils,0% blasts in peripheral blood;PR:all CR criteria met except BM blasts ≥50% decrease over pretreatment but still \>5%;HI:Hgb increase(inc) ≥1.5g/dL if baseline(BL)\<11 g/dL;pl inc≥30\*10\^9/L if BL\>20\*10\^9/L or inc from \<20\*10\^9/L to \>20\*10\^9/L and by 100%;neutrophil inc by 100%;absolute inc of \>0.5\*10\^9/L if BL\<100\*10\^9/L.For low-blast AML-CR:morphologic leukemia-free state \>1.0\*10\^9 neutrophils,≥100\*10\^9/L pl,transfusion independence,no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl\<100\*10\^9/L;PR:all CR hematological values but ≥50% decrease in BM aspirate.Number of responders determined by independent review committee(IRC) assessment.

Time frame:
From randomization until, CR, PR or HI or CR, CRi or PR (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Overall Response 2 (OR2)
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With Overall Response 2 (OR2)9494
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.891 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Absolute rate difference: -0.44 · 95% CI -10.03 to 9.15
SecondaryDuration of Complete Remission (CR)

Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML) or relapse after CR or PR (participants with HR MDS/CMML). Disease responses for HR MDS or CMML are based on the Modified IWG Response Criteria for MDS and for low-blast AML on the Revised IWG Response Criteria for AML. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).

Time frame:
From CR until first documentation of PD or relapse from CR or relapse after CR or PR (up to approximately 42 months)
Reported as:
Median · months
Duration of Complete Remission (CR)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Duration of Complete Remission (CR)13.1 (6.93 to 29.08)17.2 (13.96 to NA)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.072 · Hazard ratio (hr): 0.679 · 95% CI 0.402 to 1.146Hazard ratio was based on an unadjusted stratified Cox proportional hazard regression model with stratification factors (low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML) and treatment as a factor in the model.
SecondaryDuration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi)

Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML). Disease responses for low-blast AML were based on the Revised IWG Response Criteria for AML. CR is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).

Time frame:
From CR until first documentation of PD or relapse from CR or relapse after CR or PR (up to approximately 42 months)
Reported as:
Median · months
Duration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Duration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi)8.5 (3.02 to NA)15.0 (3.94 to NA)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.373 (P-value comparing duration of CR+CRi between treatment groups was based on 1-sided unstratified log-rank.) · Hazard ratio (hr): 0.846 · 95% CI 0.306 to 2.339Hazard ratio was based on an unadjusted unstratified Cox proportional hazard regression model with treatment as a factor in the model.
SecondaryDuration of Overall Response (OR)

Duration of OR: response to first documentation of PD or relapse from CR for low-blast AML or relapse after CR or PR for HR MDS/CMML. Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR+PR for HR MDS/CMML and CR+Cri+ PR for low-blast AML.CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR:all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR: morphologic leukemia-free state \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with CRi: fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in % of blasts in bone marrow aspirate.

Time frame:
Up to approximately 42 months
Reported as:
Median · months
Duration of Overall Response (OR)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Duration of Overall Response (OR)18.3 (8.31 to NA)17.1 (12.68 to NA)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.320 (P-value comparing duration of PR or better response between treatment groups was based on 1-sided log-rank test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.889 · 95% CI 0.542 to 1.458Hazard ratio was based on an unadjusted stratified Cox proportional hazard regression model with stratification factors (low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML) and treatment as a factor in the model.
SecondaryDuration of Overall Response 2 (OR2)

Duration of OR2: from date of first documentation of CR+PR+HI to first documentation of PD/relapse after CR/PR for responders of CR+PR+HI for HR MDS/CMML and CR,CRi,PR for low-blast AML. For HR MDS/CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb, \>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment, still \>5%; HI:Hgb inc \>=1.5 g/dL if baseline \<11 g/dL; pl inc\>=30\*10\^9/L if baseline\>20\*10\^9/L or inc from\<20\*10\^9/L to\>20\*10\^9/L by at least 100%; neutrophil inc by 100% and absolute inc of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L;PR:all CR hematological values but\>=50% decrease in bone marrow aspirate.

Time frame:
Up to approximately 42 months
Reported as:
Median · months
Duration of Overall Response 2 (OR2)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Duration of Overall Response 2 (OR2)18.3 (11.17 to 30.92)18.9 (15.01 to NA)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.151 (P-value comparing duration of overall response 2 between treatment groups was based on 1-sided log-rank test stratified by low blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.796 · 95% CI 0.514 to 1.231Hazard ratio was based on an unadjusted stratified Cox proportional hazard regression model with stratification factors (low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML) and treatment as a factor in the model.
SecondaryPercentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence

A participant was defined as RBC or platelet-transfusion independent if he/she received no RBC or platelet transfusions for a period of at least 8 weeks before the first dose of study drug through 30 days after the last dose of any study drug. Rate of transfusion independence was defined as number of participants who became transfusion independent divided by the number of participants who were transfusion dependent at Baseline.

Time frame:
Up to approximately 42 months
Reported as:
Number · percentage of participants
Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence
percentage of participantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Percentage of Participants With RBCs-transfusion Independence44.347.5
Percentage of Participants With Platelet-transfusion Independence48.945.5
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.573 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test.) · Absolute rate difference: 3.27 · 95% CI -9.02 to 15.55
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.477 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test.) · Absolute rate difference: -3.43 · 95% CI -25.84 to 18.97
SecondaryDuration of Red Blood Cells (RBCs) and Duration of Platelet-transfusion Independence and Duration of Red Blood Cells (RBCs) and Platelet-transfusion Independence

Duration of RBC and platelet transfusion independence was defined as the longest time between the last RBC and/or platelet transfusion before the start of the RBC and/or platelet transfusion-independent period and the first RBC and/or platelet transfusion after the start of the transfusion-independent period, which occurs \>= 8 weeks later.

Time frame:
Up to approximately 42 months
Reported as:
Median · months
Duration of Red Blood Cells (RBCs) and Duration of Platelet-transfusion Independence and Duration of Red Blood Cells (RBCs) and Platelet-transfusion Independence
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Duration of RBC Transfusion Independence15.6 (10.18 to 28.09)13.5 (9.07 to 16.66)
Duration of Platelet Transfusion Independence14.9 (5.09 to 23.23)11.6 (2.73 to 16.26)
Duration of Transfusion Independence12.0 (8.90 to 19.48)13.5 (10.38 to 16.66)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.774 (P-value comparing duration of RBC or platelet transfusion between treatment groups was based on 1-sided log-rank test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 1.231 · 95% CI 0.715 to 2.119HR:unadjusted Cox Proportional Hazard regression;stratification(low-blast AML,IPSS-R risk groups=very high,high,intermediate for HRMDS/CMML),treatment as factor.HR\<1:longer duration of transfusion independence in combination arm than azacitidine arm.
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.801 (P-value comparing duration of platelet transfusion between treatment groups was based on 1-sided log-rank test stratified by low blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 1.533 · 95% CI 0.567 to 4.147HR:unadjusted Cox Proportional Hazard regression;stratification(low-blast AML,IPSS-R risk groups=very high,high,intermediate for HRMDS/CMML),treatment as factor.HR\<1:longer duration of transfusion independence in combination arm than azacitidine arm.
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.450 (P-value comparing duration of RBC or platelet transfusion between treatment groups was based on 1-sided log-rank test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.968 · 95% CI 0.580 to 1.614HR:unadjusted Cox Proportional Hazard regression;stratification(low-blast AML,IPSS-R risk groups=very high,high,intermediate for HRMDS/CMML),treatment as factor.HR\<1:longer duration of transfusion independence in combination arm than azacitidine arm.
SecondaryTime to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi)

Time to first CR or PR is defined as the time from randomization to first documented CR or PR, whichever occurs first. Disease responses for HR MDS or CMML or low-blast AML cycle 6 are based on Modified IWG Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. For HR MDS or CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%; For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9/L neutrophils, pl\>=100\*10\^9/L, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.

Time frame:
From randomization until CR or PR (up to approximately 42 months)
Reported as:
Median · months
Time to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi)
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Time to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi)NA (12.12 to NA)NA (24.61 to NA)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.228 (P-value comparing time to first CR or PR or CRi (low-blast AML) between treatment groups was based on 1-sided stratified log-rank test stratified by low-blast AML,IPSS-R risk groups of very high,high,or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.880 · 95% CI 0.628 to 1.234Hazard ratio was based on an unadjusted stratified Cox proportional hazard regression model with stratification factors (low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML) and treatment as a factor in the model.
SecondaryNumber of Participants With Hematologic Improvement (HI)

Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline \>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.

Time frame:
From randomization until HI (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Hematologic Improvement (HI)
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With Hematologic Improvement (HI)7670
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.320 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test.) · Absolute rate difference: -5.46 · 95% CI -16.36 to 5.44
SecondaryNumber of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML

Inpatient hospital admission data was collected through transformation to AML (HR MDS/CMML participants) or disease progression (low-blast AML participants) or until initiation of subsequent therapy (all participants), whichever occurred first. Transformation to AML is defined, according to WHO Classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.

Time frame:
From randomization until transformation to AML or until initiation of subsequent therapy (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML39
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Rate difference: 2.64 · 95% CI -0.30 to 5.58
SecondaryTime to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death

Time to PD, relapse after CR(low-blast AML), relapse after CR or PR(HR MDS/CMML), or death,defined as time from date of randomization until date of first documentation of PD,relapse after CR(low-blast AML),relapse after CR or PR(HR MDS/CMML),or death due to any cause, whichever occurs first. In HR MDS/CMML,PD: Participants with\<5% blasts:\>=50% inc \>5% blasts, with 5%-9% blasts:\>=50% inc\>10% blasts, with 10%-19% blasts:\>=50% inc \>20% blasts,with 20%-30% blasts, at least 50% decrement from maximum remission/response in granulocytes or pl or reduction in Hgb by\>=2 g/dL/new transfusion dependence.Relapse after CR or PR: return to pretreatment bone marrow blast %/Decrement of \>=50% from maximum remission/response levels in granulocytes/pl/reduction in Hgb conc.\>=1.5 g/dL/transfusion dependence. In AML,PD:\>50% inc in bone marrow blasts to \>30% blasts,\>50% inc in circulating blasts to\>30% blasts in peripheral blood, Development of extramedullary disease/new sites of extramedullary leukemia.

Time frame:
From randomization until PD, relapse after CR, or relapse after CR or PR, or death due to any cause, whichever occurs first (up to approximately 42 months)
Reported as:
Median · months
Time to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Time to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death11.8 (10.25 to 13.31)13.1 (11.01 to 15.84)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.084 (P-value was obtained from a stratified 1-sided log-rank test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.858 · 95% CI 0.689 to 1.067Hazard ratio was based on a stratified Cox proportional hazard regression model stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML, with treatment as a factor in the model.
SecondaryChange From Baseline in Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30

The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The change from baseline at end of treatment is reported.

Time frame:
Baseline, at approximately 58 months
Reported as:
Mean · score on a scale
Change From Baseline in Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30
score on a scaleAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Global Health Status/QoL Score: Baseline60.3 ± 22.1161.6 ± 21.13
Global Health Status/QoL Score: Change from Baseline-3.0 ± 25.93-8.4 ± 26.89
Physical Functioning Score: Baseline69.4 ± 22.6375.7 ± 20.38
Physical Functioning Score: Change from Baseline-7.5 ± 22.82-13.4 ± 27.51
Role Functioning Score: Baseline66.9 ± 30.8873.7 ± 28.55
Role Functioning Score: Change from Baseline-11.8 ± 35.41-18.3 ± 36.72
Emotional Functioning Score: Baseline76.0 ± 20.9677.6 ± 22.10
Emotional Functioning Score: Change from Baselline-2.5 ± 23.80-5.9 ± 22.41
Cognitive Functioning Score: Baseline84.6 ± 18.2986.1 ± 17.60
Cognitive Functioning Score: Change from Baseline-7.2 ± 22.65-10.4 ± 24.38
Social Functioning Score: Baseline79.3 ± 25.3778.8 ± 25.82
Social Functioning Score: Change from Baseline-13.7 ± 33.89-16.5 ± 34.78
Fatigue Score: Baseline38.5 ± 25.4433.8 ± 24.24
Fatigue Score: Change from Baseline6.6 ± 26.4112.3 ± 31.22
Nausea/Vomiting Score: Baseline4.6 ± 11.394.7 ± 10.96
Nausea/Vomiting Score: Change from Baseline2.4 ± 19.081.9 ± 15.00
Pain Score: Baseline20.9 ± 25.5519.4 ± 26.42
Pain Score: Change from Baseline5.8 ± 30.366.8 ± 33.34
Dyspnoea Score: Baseline25.4 ± 29.8324.4 ± 28.90
Dyspnoea Score: Change from Baseline5.9 ± 28.955.9 ± 29.46
Insomnia Score: Baseline27.2 ± 27.9625.7 ± 30.68
Insomnia Score: Change from Baseline3.2 ± 34.324.6 ± 34.09
Appetite Loss Score: Baseline23.4 ± 29.2915.6 ± 23.99
Appetite Loss Score: Change from Baseline4.6 ± 38.6816.0 ± 34.03
Constipation Score: Baseline14.7 ± 24.7813.8 ± 22.47
Constipation Score: Change from Baseline5.5 ± 29.565.1 ± 28.42
Diarrhoea Score: Baseline7.6 ± 18.847.0 ± 16.75
Diarrhoea Score: Change from Baseline3.0 ± 22.801.9 ± 27.65
Financial Difficulties Score: Baseline14.2 ± 25.3718.4 ± 26.76
Financial Difficulties Score: Change from Baseline5.9 ± 27.037.4 ± 30.46
QLQ-C30 Summary Score: Baseline77.9 ± 14.9080.5 ± 15.08
QLQ-C30 Summary Score: Change from Baseline-6.1 ± 18.84-8.6 ± 17.75
SecondaryNumber of Participants With Overall Response in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group

Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR + PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR: morphologic leukemia-free state, \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl\<100\*10\^9/L; PR: all CR hematological values but\>=50% decrease in the percentage of blasts to 5% to 25% in bone marrow aspirate.

Time frame:
From randomization until CR, CRi and PR (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Overall Response in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
OR: HR MDS/CMML Participants1413
OR: Low-blast AML Participants1312
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.683 (P-value for HR MDS/CMML was obtained from a stratified Cochran-Mantel-Haenszel chi-square test) · Absolute rate difference: -2.85 · 95% CI -19.44 to 13.75
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.840 (P-value for Low-blast AML was obtained from an unstratified Cochran-Mantel-Haenszel chi-square test.) · Absolute rate difference: 2.36 · 95% CI -20.39 to 25.12
SecondaryEvent-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group

Event was defined as death or transformation to AML in participants with MDS or CMML, whichever occurred first. Transformation to AML was defined, according to World Health Organization (WHO) Classification as a participant having \>20% blasts in the blood or marrow and increase of blast count by 50%. Event was defined as death in participants with low-blast AML.

Time frame:
From randomization until transformation to AML if eligible or death (up to approximately 42 months)
Reported as:
Median · months
Event-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Event-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group12.8 (8.44 to 14.32)14.6 (9.99 to 18.99)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.240 (P-value comparing EFS between treatment groups was based on 1-sided log-rank test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.877 · 95% CI 0.608 to 1.263HR:unadjusted stratified Cox proportional hazard regression with stratification factors (IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\<1:better prevention of EFS in combination arm than azacitidine arm.
SecondaryOverall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group

OS was calculated from date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored as of the date the participant was last known to be alive.

Time frame:
From randomization until death (up to approximately 42 months)
Reported as:
Median · months
Overall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
monthsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Overall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group12.8 (10.84 to 14.78)16.1 (11.40 to 20.24)
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Log Rank · p = =0.145 (P-value comparing OS between treatment groups was based on 1-sided log-rank test stratified by low-blast AML, IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Hazard ratio (hr): 0.826 · 95% CI 0.580 to 1.178HR:unadjusted stratified Cox proportional hazard regression with stratification factors(IPSS-R risk groups of very high,high,intermediate) and treatment as factor in model.HR\<1: longer survival time in combination arm than azacitidine arm.
SecondaryNumber of Participants With Overall Response by Cycle 6

Responses for HR MDS/CMML are based on Modified International Working Group (IWG) Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR and PR for HR MDS/CMML and CR+CR with incomplete blood count recovery(CRi)+PR for low-blast AML. CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11g/dL hemoglobin (Hgb),\>=100\*10\^9/L platelet (pl),\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood, and PR:all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR:morphologic leukemia-free state,\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L/thrombocytopenia (pl\<100\*10\^9/L); PR:all CR hematological values but\>=50% decrease in percentage of blasts to 5%-25% in bone marrow aspirate.

Time frame:
Up to Cycle 6 (up to approximately Day 168)
Reported as:
Count of participants · Participants
Number of Participants With Overall Response by Cycle 6
ParticipantsAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Overall Response for HR MDS/CMML3629
Overall Response for Low-blast AML1322
Statistical analysis
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.261 (P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test stratified by IPSS-R risk groups of very high, high, or intermediate for HR MDS/CMML.) · Absolute rate difference: -5.14 · 95% CI -13.95 to 3.68
  • Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = =0.026 (P-value was obtained from an unstratified Cochran-Mantel-Haenszel chi-square test.) · Absolute rate difference: 22.36 · 95% CI 3.22 to 41.49

Adverse events

Collected over From first dose of study drug up to end of study (up to approximately 6.9 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine 75 mg/m^2153/220 (69.5%)145/220 (65.9%)207/220 (94.1%)
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2150/223 (67.3%)156/223 (70%)210/223 (94.2%)
Most frequent serious events
Showing 10 of 243
Most frequent serious events
EventAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Febrile neutropeniaBlood and lymphatic system disorders35/22043/223
PneumoniaInfections and infestations25/22033/223
PyrexiaGeneral disorders16/2206/223
AnaemiaBlood and lymphatic system disorders10/22013/223
Septic shockInfections and infestations6/22011/223
SepsisInfections and infestations10/2206/223
ThrombocytopeniaBlood and lymphatic system disorders4/22010/223
CellulitisInfections and infestations1/2209/223
Urinary tract infectionInfections and infestations2/2207/223
Lower respiratory tract infectionInfections and infestations6/2205/223
Most frequent other events
Showing 10 of 51
Most frequent other events
EventAzacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
ConstipationGastrointestinal disorders90/22082/223
AnaemiaBlood and lymphatic system disorders82/22078/223
NeutropeniaBlood and lymphatic system disorders77/22073/223
NauseaGastrointestinal disorders63/22078/223
ThrombocytopeniaBlood and lymphatic system disorders74/22071/223
DiarrhoeaGastrointestinal disorders51/22061/223
PyrexiaGeneral disorders56/22053/223
VomitingGastrointestinal disorders46/22051/223
AstheniaGeneral disorders42/22034/223
FatigueGeneral disorders33/22042/223

Baseline characteristics

ITT Population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Mean73.0 ± 8.2273.0 ± 7.6573 ± 7.93
Sex: Female, Male
Sex: Female, Male(Participants)Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Female8595180
Male142132274
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Hispanic or Latino263157
Not Hispanic or Latino188189377
Unknown or Not Reported13720
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
American Indian or Alaska Native246
Asian203151
Native Hawaiian or Other Pacific Islander000
Black or African American123
White189180369
More than one race000
Unknown or Not Reported151025
Region of Enrollment
Region of Enrollment(Participants)Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Australia347
Belgium8311
Brazil101828
China202
Czech Republic10616
Germany639
Spain262349
France13821
United Kingdom134
Greece302858
Israel6612
Italy14923
Japan122638
Korea, Republic of426
Poland111021
Russia221234
Turkey5510
Canada279
Mexico257
United States of America404989
Height
Height(centimeter (cm))Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Mean167.59 ± 9.439166.31 ± 10.098166.95 ± 9.783
Weight
Weight(kilogram (kg))Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Mean77.65 ± 16.14375.82 ± 15.99676.73 ± 16.078
Body Surface Area
Body Surface Area(meter square (m^2))Azacitidine 75 mg/m^2Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2Total
Mean1.89 ± 0.2281.86 ± 0.2331.88 ± 0.231
08

Study locations

242 sites
  • Southern Cancer Center - USOR
    Daphne, Alabama 36526, United States
  • Southern Cancer Center - USOR
    Mobile, Alabama 36607, United States
  • Southern Cancer Center - USOR
    Mobile, Alabama 36608, United States
  • Southern Cancer Center- USOR
    Mobile, Alabama 36608, United States
  • Southeastern Regional Medical Center - CTCA - PPDS
    Goodyear, Arizona 85338, United States
  • Arizona Oncology Associates (Orange HOPE) - USOR
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates (Rudasill HOPE) - USOR
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates (Wilmot HOPE) - USOR
    Tucson, Arizona 85711, United States
  • Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc
    Corona, California 92879, United States
  • Compassionate Cancer Care Medical Group Inc
    Fountain Valley, California 92708, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Emad Ibrahim, MD, Inc
    Redlands, California 92373, United States
  • Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc
    Riverside, California 92501, United States
  • Rocky Mountain Cancer Centers (Aurora) - USOR
    Aurora, Colorado 80012, United States
  • Rocky Mountain Cancer Centers (Boulder) - USOR
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers (Colorado Springs) - USOR
    Colorado Springs, Colorado 80907, United States
  • Quest Diagnostics, INC
    Denver, Colorado 80209, United States
  • Colorado Blood Cancer Institute - PPDS
    Denver, Colorado 80218, United States
  • Presbyterian Saint Lukes Medical Center Laboratory
    Denver, Colorado 80218, United States
  • Presbyterian/St. Luke's Medical Center
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers (Williams) - USOR
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers (Denver) - USOR
    Denver, Colorado 80220, United States
  • Kaiser Foundation Health Plan
    Denver, Colorado 80239, United States
  • Laboratory Corporation of America
    Englewood, Colorado 80112, United States
  • Rocky Mountain Cancer Centers (Lakewood) - USOR
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers (Littleton) - USOR
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer Centers (Lone Tree) - USOR
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers (Longmont) - USOR
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers (Parker) - USOR
    Parker, Colorado 80138, United States
  • Rocky Mountain Cancer Centers (Pueblo) - USOR
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers (Thornton) - USOR
    Thornton, Colorado 80260, United States
  • Medstar Research Institute
    Washington D.C., District of Columbia 20010, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Altamonte Springs, Florida 32701, United States
  • SCRI Florida Cancer Specialists South
    Bonita Springs, Florida 34135, United States
  • SCRI Florida Cancer Specialists South
    Bradenton, Florida 34209, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Brandon, Florida 33511, United States
  • SCRI Florida Cancer Specialists South
    Cape Coral, Florida 33914, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Clearwater, Florida 33761, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33905, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33908, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Gainesville, Florida 32605, United States
  • Mayo Clinic Jacksonville - PPDS
    Jacksonville, Florida 32224, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Largo, Florida 33770, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Lecanto, Florida 34461, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Baptist Health System (N Kendall) - USOR
    Miami, Florida 33176, United States
  • SCRI Florida Cancer Specialists South
    Naples, Florida 34102, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    New Port Richey, Florida 34655, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Ocala, Florida 34471, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Orange City, Florida 32763, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Orlando, Florida 32806, United States
  • SCRI Florida Cancer Specialists South
    Port Charlotte, Florida 33980, United States
  • SCRI Florida Cancer Specialists South
    Sarasota, Florida 34232, United States
  • SCRI Florida Cancer Specialists South
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Spring Hill, Florida 34608, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    The Villages, Florida 32159, United States
  • SCRI Florida Cancer Specialists South
    Venice, Florida 34285, United States
  • SCRI Florida Cancer Specialists South
    Venice, Florida 34292, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Winter Park, Florida 32792, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Saint Alphonsus Regional Medical Center
    Boise, Idaho 83706, United States
  • Saint Alphonsus Caldwell Cancer Care Center
    Caldwell, Idaho 83605, United States
  • Saint Alphonsus Medical Center
    Nampa, Idaho 83687, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Menorah Medical Center
    Overland Park, Kansas 66209, United States
  • Centerpoint Medical Center
    Independence, Missouri 64057, United States
  • HCA Midwest Health - SCRI - PPDS
    Kansas City, Missouri 64132, United States
  • Research Medical Center
    Kansas City, Missouri 64132, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • New Jersey Hematology Oncology Associates LLC
    Brick, New Jersey 08724, United States
  • John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • New Jersey Hematology and Oncology
    Toms River, New Jersey 08755, United States
  • Weill Cornell Medical Center - Monitoring Location
    New York, New York 10021, United States
  • Weill Cornell Medical Center
    New York, New York 10021, United States
  • Strong Memorial Hospital
    Rochester, New York 14642, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45211, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45230, United States
  • Oncology Hematology Care Inc - USOR
    Cincinnati, Ohio 45236, United States
  • Oncology Hematology Care Inc - USOR
    Cincinnati, Ohio 45242, United States
  • Fairview Hospital
    Cleveland, Ohio 44111, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oncology Hematology Care, Inc - Fairfield
    Fairfield, Ohio 45014, United States
  • Hillcrest Hospital Cancer Care Center
    Mayfield, Ohio 44124, United States
  • St. Luke's Hospital
    Bethlehem, Pennsylvania 18015, United States
  • St. Luke's University Health Network
    Easton, Pennsylvania 18045, United States
  • Greenville Health System
    Easley, South Carolina 29640, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Greenville Health System Cancer Institute
    Greenville, South Carolina 29615, United States
  • Greenville Health System
    Greer, South Carolina 29650, United States
  • Greenville Health System
    Seneca, South Carolina 29672, United States
  • Greenville Health System
    Spartanburg, South Carolina 29307, United States
  • Tennessee Oncology - DICKSON - SCRI - PPDS
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology - FRANKLIN - SCRI - PPDS
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology - GALLATIN - SCRI - PPDS
    Gallatin, Tennessee 37066, United States

Showing the first 100 of 242 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ades L, Girshova L, Doronin VA, Diez-Campelo M, Valcarcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334. PubMed 35728048 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in May 2021, 42 months.

Results were first posted in Sep 2022, 1 year 3 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 42 months is close to that.

Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2017
First posted
Aug 31, 2017
StartActual
Nov 28, 2017
Primary completionActual
May 28, 2021
CompletionActual
Oct 14, 2024
Results first posted
Sep 22, 2022
Last update
Oct 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03268954
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Nov 28, 2017
Primary completion
May 28, 2021
Completion
Oct 14, 2024
Results posted
Sep 22, 2022
Last update
Oct 29, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion